Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...

Valeo Financial Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $88 and keeps an Overweight rating on the ...

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a ...